deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT02455557

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma

Sponsor: Roswell Park Cancer Institute

Conditions Glioblastoma Gliosarcoma
Interventions Laboratory Biomarker Analysis Montanide ISA 51 VG SVN53-67/M57-KLH Peptide Vaccine Sargramostim Temozolomide
Updated 28 times since 2017 Last updated: Feb 5, 2026 Started: May 4, 2015 Primary completion: Oct 23, 2019 Completion: Mar 2, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Glioblastoma and Gliosarcoma and is currently ongoing. Roswell Park Cancer Institute leads this study, which shows 28 recorded versions since 2015 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Mar 2018 · 10 months · monthly snapshot~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Nov 2018 · 4 months · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~Apr 2019 · 59 days · monthly snapshot~Apr 2019 – ~Aug 2019 · 4 months · monthly snapshot~Aug 2019 – ~Mar 2020 · 7 months · monthly snapshot~Mar 2020 – ~Jun 2020 · 3 months · monthly snapshot~Jun 2020 – ~Aug 2020 · 2 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Apr 2022 · 7 months · monthly snapshot~Apr 2022 – ~Apr 2023 · 12 months · monthly snapshot~Apr 2023 – ~Apr 2024 · 12 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~Sep 2025 · 5 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – ~Feb 2026 · 3 months · monthly snapshot~Feb 2026 – present · 7 months · monthly snapshot

Change History

28 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Nov 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Apr 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2024 — Apr 2025 [monthly]

    Active Not Recruiting PHASE2

▶ Show 23 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Apr 2023 — Apr 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Apr 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE2

  6. Apr 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  7. Mar 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE2

  8. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE2

  9. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  10. Jun 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE2

  11. Mar 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE2

  12. Aug 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE2

  13. Apr 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE2

  14. Feb 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE2

  15. Dec 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE2

  16. Nov 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE2

  17. Jul 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE2

  18. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE2

  19. Apr 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  20. Mar 2018 — Apr 2018 [monthly]

    Recruiting PHASE2

  21. May 2017 — Mar 2018 [monthly]

    Recruiting PHASE2

  22. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE2

  23. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

May 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Roswell Park Cancer Institute
Data source: Roswell Park Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations